Citigroup
TRDA icon

Citigroup’s Entrada Therapeutics TRDA Stock Holding History

Citigroup’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
14,790
+9,937
+205% +$95.3K ﹤0.01% 4635
2026
Q1 		$61.2K Buy
4,853
+729
+18% +$8.35K ﹤0.01% 4448
2025
Q4 		$42.4K Buy
4,124
+2,075
+101% +$17.5K ﹤0.01% 4633
2025
Q3 		$11.9K Sell
2,049
-11,357
-85% -$66.4K ﹤0.01% 4965
2025
Q2 		$90.1K Sell
13,406
-5,180
-28% -$41.7K ﹤0.01% 4457
2025
Q1 		$168K Sell
18,586
-1,292
-6% -$16.1K ﹤0.01% 4298
2024
Q4 		$344K Buy
19,878
+1,896
+11% +$34.4K ﹤0.01% 4070
2024
Q3 		$287K Buy
17,982
+12,439
+224% +$196K ﹤0.01% 4102
2024
Q2 		$79K Sell
5,543
-50,744
-90% -$721K ﹤0.01% 4330
2024
Q1 		$798K Buy
56,287
+53,177
+1,710% +$752K ﹤0.01% 3209
2023
Q4 		$46.9K Buy
3,110
+3,079
+9,932% +$45.6K ﹤0.01% 4555
2023
Q3 		$490 Sell
31
-6,632
-100% -$104K ﹤0.01% 5212
2023
Q2 		$101K Sell
6,663
-55,360
-89% -$763K ﹤0.01% 4243
2023
Q1 		$899K Buy
62,023
+10,981
+22% +$147K ﹤0.01% 2644
2022
Q4 		$690K Buy
51,042
+49,459
+3,124% +$867K ﹤0.01% 2938
2022
Q3 		$25K Buy
1,583
+1,489
+1,584% +$18.9K ﹤0.01% 4661
2022
Q2 		$1K Sell
94
-319
-77% -$2.42K ﹤0.01% 6098
2022
Q1 		$4K Sell
413
-1,980
-83% -$21.2K ﹤0.01% 5913
2021
Q4 		$41K Buy
+2,393
New +$58K ﹤0.01% 5164

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Citigroup's TRDA Position: Q2 2026 in Review

Citigroup increased its Entrada Therapeutics (TRDA) stake by 205% in Q2 2026, buying an estimated $95.3K and bringing the position to 14,790 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #4635.

Citigroup first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $899K in Q1 2023. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Citigroup held 14,790 shares of Entrada Therapeutics worth $109K as of Q2 2026.
  • Citigroup bought 9,937 Entrada Therapeutics shares in Q2 2026, an estimated $95.3K.
  • Entrada Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4635 holding.
  • Citigroup first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Citigroup's Entrada Therapeutics position peaked at $899K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.